Barrett's Esophagus Clinical Trials
A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 349 clinical trials
Collection of bone marrow aspirate and biopsies for research
Some of the cells of the immune system reside in the bone marrow, and can only be obtained by inserting a needle into the bone marrow (typically done through the back of the hip bone). This is a standard clinical diagnostic procedure, but in this case done for the purpose …
- 0 views
- 19 Feb, 2024
- 1 location
SMaRT Blood: Single-unit versus Multiple-unit pRBC Transfusion in non-acute postpartum anemia
Currently, many doctors give 2 units, or packets, of blood because they expect that everyone will need 2. However, it may be better to only give 1 unit at a time to raise blood counts and relieve the symptoms of anemia, such as dizziness or feeling tired. The purpose of …
- 0 views
- 19 Feb, 2024
- 1 location
A Randomized Placebo Surgery Controlled Double-blinded Multi-center Phase 2 Clinical Trial Evaluating Efcacy and Safety of VY-AADC02 in Advanced Parkinsons Disease with Motor Fluctuations
VY-AADC02 involves placing a gene in the brain that programs brain cells to produce an enzyme (protein) called AADC (aromatic amino acid decarboxylase) in patients with Parkinson's Disease.The study group to which you are assigned will be chosen by chance (like ipping a coin); this is known as randomization. Subjects …
- 0 views
- 19 Feb, 2024
- 1 location
KCP-330-020
The purpose of this study is to see if the investigational drug, selinexor, has any effects in eligible participants with advanced unresectable dedifferentiated liposarcoma (DDLS). Selinexor will be given at a fixed oral dose of 60mg or placebo twice weekly on Days 1 and 3 during Weeks 1-6 of each …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer
All patients will receive binimetinib at a standard dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer that has a mutation in a key cancer gene called KRAS, and the cancer has spread to …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 23220 Vitamin D Receptor Agonist Paricalcitol Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer
In the run-in safety study, the safety of adding two formulations (IV or Oral) of paricalcitol to a standard chemotherapy program of gemcitabine and nab-paclitaxel will be evaluated. The randomized phase 2 study will evaluate the efficacy of paricalcitol when added to gemcitabine and nab-paclitaxel
- 0 views
- 19 Feb, 2024
- 1 location
Study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 subjects with Leber's Congenital Amourosis (LCA) Due to to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene.
This study is being done to find out if the study drug works and can be tolerated in patients with LCA10.
- 0 views
- 19 Feb, 2024
- 1 location
Cancer detection rate of Abbreviated (Fast) Breast MRI (AB-MR) after negative Digitial Breast Tomosynthesis in Women status post Conservation Therapy (BCT)
The goal of the supplemental screening with fast breast MRI would be to detect subclinical disease not detected on mammography and thus improve patient outcomes.
- 0 views
- 19 Feb, 2024
- 1 location
AN EXPLORATORY OPEN-LABEL PROOF-OF-CONCEPT PHASE 2A STUDY OF MAVACAMTEN (MYK-461) IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF) AND CHRONIC ELEVATION OF CARDIAC TROPONIN I AND/OR NT-PROBNP
The study will include an up to 7-week screening period (with an initial biomarker prescreen that may be performed remotely via home health nurse), a 26-week treatment period, and an 8-week posttreatment follow-up period.
- 0 views
- 19 Feb, 2024
- 1 location
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
The dosing of ketone drink administration (approximately 65 mL) will be weight based (714 mg/kg), which is crucial to replicating ketone levels between participants.22 The KE drink will be administered approximately 45 minutes prior to FDG injection as concentrations of ~3 mmol/L are reached within 60 minutes16 18 .
- 0 views
- 19 Feb, 2024
- 1 location